Princess Margaret Phase I Consorium (PMP1C)

由萧丽莲博士领导的玛格丽特公主第一期财团(PMPIC)由公主 玛格丽特癌症中心(PM)作为其主要学术组织(LAO)和三个附属组织 (Ao)：莫菲特癌症中心、朱拉文斯基癌症中心和不列颠哥伦比亚省癌症机构 (国商银行)。PMPIC的具体目标与ET-CTN的目标密切相关：1)开展 创新、协调、高效、合规和高影响的早期临床试验 实验疗法，旨在解决不重复研究的重要问题 由制药行业或其他来源支持；2)采用团队科学跨学科 内外协同提高抗癌新药最优评价水平 单独或联合使用；3)促进生物标志物的开发和相关科学研究 通过对登记在ET-CTN上的患者的肿瘤进行全面的分子表征 阐明作用机制的试验，以及治疗反应和/或耐药性的预测因素；以及 4)重视培训和教育，促进初级侦查员的职业发展。 PMPIC致力于积极领导ET-CTN早期试验，并作为有意义的 由其他财团牵头的ET-CTN试验的合作伙伴。有一个由方向盘支持的强有力的领导 翻译研究、临床研究和运营核心委员会，PMPIC组成团队 采用科学方法进行最相关的新药早期临床试验 组合。PMPIC登记的所有患者都将接受全面的分子鉴定 使用先进的基因分型或靶向测序方法来帮助识别药物敏感性或 抵抗。这些数据，连同药理学、免疫功能和定量成像数据，将 实现与临床结果最优的生物学相关性。利用来自其他公司的资源 包括制度支持在内的来源，PMP1C下一步将进一步推进整个外显子组/全基因组 在该奖项的时间框架内，在未来5年内进行代测序技术。

The Princess Margaret Phase I Consortium (PMPIC), led by Dr. Lillian Siu, consists of the Princess Margaret Cancer Centre (PM) as its Lead Academic Organization (LAO) and three Affiliated Organizations (AO): Moffitt Cancer Center (MCC), Juravinski Cancer Centre (JCC) and British Columbia Cancer Agency (BCCA). The Specific Aims of PMPIC resonate closely with the goals of the ET-CTN: 1)To conduct innovative, coordinated, efficient, regulatory-compliant and high impact early phase clinical trials in experimental therapeutics, which are designed to address important questions that do not duplicate research supported by the pharmaceutical industry or other sources; 2) To adopt a team science interdisciplinary approach with internal and external collaborations to enhance the optimal evaluation of novel anticancer agents alone or in combination; 3) To accelerate biomarker development and correlative sciences research through comprehensive molecular characterization of tumors obtained from patients enrolled on ET-CTN trials to elucidate mechanism of action, as well as predictors of therapeutic response and/or resistance; and 4) To emphasize training and education to foster career development of junior investigators. PMPIC is committed to actively lead ET-CTN early phase trials as well as to contribute as a meaningful partner to ET-CTN trials led by other Consortia. With a strong Leadership that is supported by the Steering Committee, Translational Research, Clinical Research and Operational Cores, PMPIC embraces a team science approach to conduct the most relevant early phase clinical trials of novel agents alone or in combination. All patients enrolled by the PMPIC will undergo comprehensive molecular characterization using advanced genotyping or targeted sequencing approaches to help identify drivers of drug sensitivity or resistance. This data, along with pharmacological, immune function, and quantitative imaging data, will enable the most optimal biological correlation with clinical outcome. Leveraging resources from other sources including institutional support, the PMP1C will further advances whole exome/whole genome next generation sequencing technologies within the timeframe of this award in the next 5 years.